Summary of Allegations
At a hearing on September 23 and 24, 2015, a Panel of the Discipline Committee made findings of professional misconduct against Mr. Magdy Salama, while engaged in the practice of pharmacy as director, shareholder, Designated Manager and/or dispensing pharmacist at Hanin Drug Mart in Toronto, Ontario, with respect to the following incidents:
- that he submitted accounts or charges for services that he knew or reasonably ought to have known were false or misleading to the Ontario Drug Benefit program
- that he falsified pharmacy records relating to his practice in relation to claims made to the Ontario Drug Benefit program
- that he failed to ensure that the Pharmacy complied with all legal requirements, including but not limited to, requirements regarding record keeping, documentation, and billing the Ontario Drug Benefit Plan
- that he failed to actively and effectively participate in the day-to-day management of the Pharmacy, including but not limited to, drug procurement and inventory management, record keeping and documentation, professional supervision of pharmacy personnel and billing.
In particular, the Panel found that he
- failed to maintain a standard of practice of the profession
- falsified records relating to his practice
- signed or issued, in his professional capacity, a document that he knew contained a false or misleading statement
- submitted accounts or charges for services that he knew to be false or misleading
- contravened a federal or provincial law or municipal by-law with respect to the distribution, sale or dispensing of any drug or mixture of drugs, and in particular, sections 5, 6 and 15(1)(b) of the Ontario Drug Benefit Act, R.S.O. 1990, c. O.10, as amended, and/or Ontario Regulation 201/96 made thereunder
- engaged in conduct or performed an act or acts relevant to the practice of pharmacy that, having regard to all the circumstances, would reasonably be regarded by members of the profession as disgraceful, dishonourable or unprofessional.
Submissions with respect to the Order will be heard on April 11, 2018.